These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24985059)

  • 1. Nras in melanoma: targeting the undruggable target.
    Mandalà M; Merelli B; Massi D
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):107-22. PubMed ID: 24985059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching for the Chokehold of NRAS Mutant Melanoma.
    Posch C; Vujic I; Monshi B; Sanlorenzo M; Weihsengruber F; Rappersberger K; Ortiz-Urda S
    J Invest Dermatol; 2016 Jul; 136(7):1330-1336. PubMed ID: 27160069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.
    Johnson DB; Smalley KS; Sosman JA
    Clin Cancer Res; 2014 Aug; 20(16):4186-92. PubMed ID: 24895460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of NRAS-mutant melanoma.
    Johnson DB; Puzanov I
    Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
    Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.
    Basu D; Salgado CM; Bauer BS; Johnson D; Rundell V; Nikiforova M; Khakoo Y; Gunwaldt LJ; Panigrahy A; Reyes-Múgica M
    Neuro Oncol; 2016 Apr; 18(4):528-37. PubMed ID: 26354928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in targeted therapy for melanoma.
    Friedlander P; Hodi FS
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process.
    Gonçalves PR; Rocha-Brito KJ; Fernandes MR; Abrantes JL; Durán N; Ferreira-Halder CV
    Tumour Biol; 2016 Oct; 37(10):14049-14058. PubMed ID: 27502397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.
    Vujic I; Sanlorenzo M; Esteve-Puig R; Vujic M; Kwong A; Tsumura A; Murphy R; Moy A; Posch C; Monshi B; Rappersberger K; Ortiz-Urda S
    Oncotarget; 2016 Feb; 7(6):7297-306. PubMed ID: 26771141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells.
    Cisilotto J; Ferreira M; Filippin-Monteiro FB; Bortoluzzi AJ; Sa MM; Creczynski-Pasa TB
    Anticancer Agents Med Chem; 2015; 15(3):353-62. PubMed ID: 25469513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles.
    Vora HD; Johnson M; Brea RJ; Rudd AK; Devaraj NK
    ACS Chem Biol; 2020 Aug; 15(8):2079-2086. PubMed ID: 32568509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential oncogenic potential of activated RAS isoforms in melanocytes.
    Whitwam T; Vanbrocklin MW; Russo ME; Haak PT; Bilgili D; Resau JH; Koo HM; Holmen SL
    Oncogene; 2007 Jul; 26(31):4563-70. PubMed ID: 17297468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.